Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full
Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of a Q2 revenue beat, an adjusted EPS beat, and an explicit increase to full-year revenue and earnings guidance, which can shift consensus estimates and valuation support.
Market read
Traders can reassess near-term consensus and risk for ILMN after a reported beat and guidance increase, with immediate post-report price strength cited.
What to watch
The text does not break out product mix, backlog, or cash flow, so traders may be underestimating sustainability and working-capital effects behind EPS and margin changes.
Background
Illumina is a genomics sequencing and microarray technology provider; the article frames results against both Wall Street expectations and longer-term growth trends.
Ticker impact
Illumina reported Q2 CY2026 revenue of $1.16B (+9.4% YoY) and raised full-year revenue guidance to $4.62B midpoint.
Likely supports continued upside bias versus pre-report expectations, though magnitude may be limited given the article’s emphasis on historically weak growth.
The article provides concrete earnings metrics (revenue, EPS beat) and explicit guidance increase, plus notes the stock jumped 3.8% immediately after reporting, indicating market repricing.
Market effects
A sequencing-tech revenue beat with guidance lift can modestly improve sentiment toward genomics tools and clinical sequencing demand.
Primarily US-listed healthcare/biotech sentiment; limited direct regional spillover described.
No explicit global macro or international regulatory drivers cited beyond Wall Street expectations.
Counterpoint
Despite the beat, the article highlights weak longer-term growth (flat organic revenue over two years), suggesting the upside may be more cyclical than structural.
Key entities
- public_companyIllumina
Reported Q2 CY2026 revenue and adjusted EPS, and increased full-year guidance; stock rose 3.8% immediately after reporting.
